Preparation method of dendritic cell (DC) vaccine loaded with autologous tumor associated holoantigen

Abstract

The invention belongs to preparation of biological cell formulations, and in particular relates to a preparation method of dendritic cell (DC) vaccine loaded with autologous tumor associated holoantigen. The preparation method comprises the following steps: preparing the autologous tumor associated holoantigen, collecting and separately culturing DCs, impacting the DCs by the autologous tumor associated holoantigen, maturing the DCs and preparing autologous tumor antigen specific DC vaccine. The invention solves the problems in the prior art that the immunogenicity of tumor antigen is not strong enough, the antigen target spots are incomplete, the tumor antigens of most tumor patients are difficult to acquire, and the like. The DC vaccine provided by the invention has the advantages of effectively inducing tumor antigen specific cytotoxic T lymphocyte (CTL) in vitro and in vivo, efficiently generating specific cytotoxicity on tumors, having high overall effective rate and no obvious toxic side effects in clinical application, and the like.

Description

technical field [0001] The invention belongs to the preparation of biological preparations, in particular to a preparation method of a dendritic cell vaccine loaded with autologous tumor-associated whole antigens. Background technique [0002] Tumors occur frequently in our country, and its incidence and mortality have been increasing year by year in recent years, becoming one of the main factors threatening human health. Tumor is a systemic disease. In traditional surgery, radiotherapy and chemotherapy, surgery and radiotherapy are local treatment methods. Although they can effectively reduce the tumor burden, it is difficult to solve the problem of metastasis and recurrence. Chemotherapy is the only systemic treatment among traditional methods, but it has defects such as low effective rate (about 30%), large side effects, drug resistance, and severe immunosuppression, which limit its clinical application. Therefore, the clinic expects a systemic treatment with less side e...

AI Technical Summary

Problems solved by technology

[0009] However, the clinical application of DC vaccines is currently limited. First, the immunogenicity of the tumor antigens used is not strong enough. Second, the tumor antigens of most tumor patients are not easy to obtain. Third, the clinical efficacy is limited

Tumor-specific antigenic proteins / peptides and tumor-associated antigenic proteins / peptides have weak antigenicity, a single target for activating immunity, and poor immunogenicity of vaccines. Currently, for most tumors, their effective tumor specificity cannot be determined or related antigens, and are restricted by HLA, making it difficult to be widely used

Although tumor cell mRNA can represent the whole tumor antigen, the preparation process is complex and easy to degrade, resulting in the absence of antigen, which is difficult to promote in clinical practice

Tumor cell lysate, etc., the protein or polypeptide containing the whole antigen of tumor cells, has strong and complete antigenicity, and the antigen targets carried by DC cells after uptake and processing are comprehensive, which can stimulate the body to produce comprehensive anti-tumor immunity, so it is a good However, the tumor cells of many patients are difficult to obtain or the number of cells is insufficient, which is an urgent clinical problem to be solved

The application of wax block specimens to prepare tumor whole antigens, although the source of autologous tumor antigens has been expanded, it is difficult to avoid the loss of a large amount of antigenic components in the process of specimen processing, which also limits its clinical application

DC vaccines prepared with the above antigens have been found to have limited curative effect through clinical application

Images